Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.86 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.86 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | F11 | P03951 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150306 | 0.93 | LPL (1.00) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL29037583 | 0.83 | LPL (0.79) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL257620 | 0.83 | LPL (0.88) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL3792599 | 0.81 | MGLL (0.63) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL18394607 | 0.80 | CA2 (0.78) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL1702558 | 0.80 | TP53 (0.56) | LPLLIPGCA2EGFRTSHR | |
| SCHEMBL806835 | 0.80 | CA2 (0.78) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL2776957 | 0.80 | TP53 (0.56) | LPLLIPGCA2EGFRTSHR | |
| SCHEMBL13667445 | 0.80 | CA2 (0.78) | LPLLIPGCA2CA1MGLL | |
| SCHEMBL13454827 | 0.79 | CA1 (0.89) | LPLLIPGCA2CA1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021119249-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10113116-B2 | Liquid crystal compound and liquid crystal composition employing the same | DAXIN MATERIALS CORPORATION (TW) | 2018-10-30 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| EP-2520575-B1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | GEN INC ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160222295-A1 | LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL COMPOSITION EMPLOYING THE SAME | DAXIN MATERIALS CORPORATION (TW) | 2016-08-04 | — | — | US | disclosed |
| CN-102725287-B | 1,3, 4-oxadiazole-2-carboxamide compounds | PHARMA IP GENERAL INC ASS | 2015-07-01 | — | — | CN | disclosed |
| US-7749403-B2 | Monofluorinated terphenyl compound having alkenyl, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20090206300-A1 | MONOFLUORINATED TERPHENYL COMPOUND HAVING ALKENYL, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2009-08-20 | — | — | US | disclosed |
| US-20090206300-A1 | MONOFLUORINATED TERPHENYL COMPOUND HAVING ALKENYL, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2009-08-20 | — | — | US | disclosed |
| WO-2008146720-A1 | INDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | CANON KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | WO | disclosed |
| EP-1970362-A1 | MONOFLUORINATED TERPHENYL COMPOUND HAVING ALKENYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | LPL 1082/4885LIPG 2028/4885CA2 3950/4885 |
| US-10113116-B2 | Liquid crystal compound and liquid crystal composition employing the same | ZYX, MLX, NPM1 | LPL 993/4885LIPG 2470/4885CA2 2293/4885 |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | LPL 2387/4885LIPG 883/4885CA2 561/4885 |
| US-20160222295-A1 | LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL COMPOSITION EMPLOYING THE SAME | ZYX, MLX, NPM1 | LPL 993/4885LIPG 2470/4885CA2 2293/4885 |
| US-20090206300-A1 | MONOFLUORINATED TERPHENYL COMPOUND HAVING ALKENYL, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, FZD7, HTR1D | LPL 2855/4885LIPG 3845/4885CA2 4348/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LPL 3816/4885LIPG 3010/4885CA2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.